OVCAR-3

OVCAR-3 (Ovarian Cancer CDX Model) 

The OVCAR-3 ovarian cancer cell line was derived from ascites of a patient with advanced ovarian adenocarcinoma. It is resistant to adriamycin and platinum-based chemotherapies. OVCAR-3 is widely used in drug discovery focused on resistant ovarian cancer. Its reproducibility supports translational oncology pipelines. 

Key Features: 

• Derived from advanced ovarian adenocarcinoma. 

• Resistant to adriamycin and platinum drugs. 

• Epithelial morphology. 

• Tumorigenic in xenograft systems. 

Applications: 
OVCAR-3 supports studies of resistance mechanisms in ovarian cancer. Researchers apply it in biomarker development and drug discovery programs. It is useful for testing novel therapeutics targeting chemotherapy-resistant disease. Its stable performance ensures reliability in translational research.